Potential Future Consideration for Imaging and Blood-Based Biomarkers for Precision Medicine in Lung Cancer
Total Page：16
File Type：pdf, Size：1020Kb
713-715 Editorial Potential future consideration for imaging and blood-based biomarkers for precision medicine in lung cancer Feng-Ming (Spring) Kong1, Fred R. Hirsch2, Mitchell Machtay3 1IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IU, USA; 2Division of Medical Oncology, School of Medicine, University of Colorado Denver, Aurora, CO, USA; 3Department of Radiation Oncology, Case Western University Hospital, Cleveland, OH, USA Correspondence to: Feng-Ming (Spring) Kong, MD, PhD. IU Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IU, USA. Email: [email protected]. Submitted Sep 20, 2017. Accepted for publication Sep 28, 2017. doi: 10.21037/tlcr.2017.09.11 View this article at: http://dx.doi.org/10.21037/tlcr.2017.09.11 In this issue, we have reviewed the current status of imaging past NCI Cooperative Group Programs have joined their and blood-based biomarkers in translational lung cancer collective strengths to form this new IROC group. IROC research. Clearly, some small but important initial steps assures high-quality data for clinical trials designed to have been made toward realizing precision medicine improve clinical outcomes for cancer patients worldwide. approaches for this disease, and research in this area has IROC provides five quality assurance core functions: site revealed significant opportunities to address unmet needs qualification, protocol development support, credentialing, and validate imaging and blood-based biomarkers in clinical data management (pre- and post-review), and case review. trials. The continuous success of IROC has established the very We are pleased to note that the NCI-funded National first step for implementing imaging for precision medicine Clinical Trials Network NCTN has recognized the role of in clinical trials. functional imaging in clinical trials and precision medicine. Looking into the future, we envision even greater RTOG (now NRG Oncology) began functional imaging opportunities to apply novel imaging techniques within work in 2003. The Alliance (which was created from national cooperative group trials. Built on the foundational the merger of CALGB, ACOSOG and the NCCTG) role of IROC, and early phase work from cancer centers and SWOG introduced imaging committees upon their and the Cooperative Groups, imaging for consistent formation in 2012. Most notably, the formation of ECOG- outcome assessment and as integrated biomarkers have ACRIN elevated the importance of imaging to one of its become feasible. We can now apply standardized imaging two primary missions in that new Group. procedures set by the Quantitative Imaging Biomarker To further provide integrated imaging and radiation Alliance (QIBA) and tools developed by the Quantitative quality control programs in support of the NCTN Imaging Network (QIN) to perform correlative studies for program, the NCI funded a quality assurance core facility multicenter cooperative trials to maximize the information known as Imaging and Radiation Oncology Core (IROC) gained via imaging for guidance of precision medicine. in 2014. As detailed by Xiao and Rosen in this issue (1), Specific areas of focus in lung cancer imaging-based IROC has been tasked with providing standardizing biomarkers that will push this field forward can be radiotherapy and imaging quality, data management services multidimensional. CT and positron emission tomography to enforce consistent quality among innovative technical (PET) imaging biomarkers provide complementary developments in imaging, and new therapeutic modalities knowledge to analyses from tissue biospecimens. CT for multi-institutional clinical trials. This core service scans, widely available for all clinical trial patients, can now organization provides scientific and technical expertise in be assessed with greater sophistication, using radiomic both imaging and radiotherapy quality assurance to the techniques, at for prognosis and treatment response entire clinical network. A number of QA Centers in the prediction. FDG-PET and other molecular imaging tests © Translational lung cancer research. All rights reserved. tlcr.amegroups.com Transl Lung Cancer Res 2017;6(6):713-715 714 Kong et al. Imaging and blood based biomarkers for precision medicine as robust predictors of tumor control and patient survival as integrated markers in therapeutic trials, which will lead would support the use of molecular imaging as an accepted to their eventual use as integral biomarkers in therapeutic endpoint in some therapy trials. MRI may also provide clinical trials and clinical practice. Ultimately, validated another dimension of assessment for lung and mediastinal imaging biomarkers for outcome prediction and early tissue analyses. imaging as a surrogate endpoint could reduce sample size To advance the role of imaging in precision medicine and study duration, resulting in significant reductions in cost for clinical trials, specific tasks that can be implemented, for new clinical trials. Most importantly, the development particularly in cooperative groups include (but are not of imaging biomarkers can advance precision medicine to limited to): a new horizon for improving treatment outcome in each (I) Identify imaging resources available in the group individual patient. archive system led by IROC, and develop strategies For blood-based biomarkers, we have reviewed the to maximize what can be learned from imaging roles of these biomarkers for precision treatment with an outcome correlates from the completed clinical emphasis on the methodology for identifying and utilizing trials. the biomarkers in an integrated approach for future (II) Mandate submission of high-quality imaging clinical trials and practice. Circulating tumor cells and/or data for ongoing trials. Such imaging data should circulating tumor DNA have shed some light on strategies include all scans associated with pre-treatment for selected molecular targeted systematic therapies. staging, target delineation and treatment planning, Some genomic, cytokine, and/or proteomic markers have and follow-up imaging used for assessment of furthermore shown potential in predicting treatment treatment response and tumor progression. toxicity. We must note that the field of blood-based markers (III) Validate CT, FDG-PET, and other imaging tests as is still in its infancy for guiding precision medicine. Blood robust predictors of patient survival, to support the biomarker studies—either for discovery or validation—are use of imaging as an accepted ‘surrogate’ endpoint still mostly lacking in cooperative group lung cancer studies. in later-stage therapy trials. While all of the cooperative groups have long since started (IV) Standardize the modern imaging tests needed for blood, serum, or plasma biospecimen banking for “future clinical trial eligibility for each disease site and each use”, sample quality assurance and infrastructure for such clinical trial. an important effort are still needed in all the collaborative (V) Implement prospective imaging biomarker groups. correlative studies in future trials. To advance the role of blood-based biomarkers in (VI) Develop clinical trials to test new imaging tools precision medicine, specific tasks that will increase the and/or new applications of conventional imaging to efficiency of this work include (but are not limited to): direct treatment interventions, like personalized (I) Sort banked blood samples for appropriateness adaptive treatment as described in RTOG1106. in biomarker testing for validity. Proteomic or (VII) Develop new predictive and early-response cytokine tests using samples collected without molecular imaging biomarkers, using probes appropriate temperature control or duration of designed to quantify specific therapeutic targets or blood setting may generate artificial results, as these specific pharmacodynamics or radiation therapy samples are most likely degraded. Genomic testing responses, to assess the efficacy treatment in near- may be the only possibility for samples collected real-time. and stored without rigorous quality control. The cooperative leadership and NCI funding mechanisms (II) Follow NCI’s best practice guidelines (https:// must promote and support correlative studies to discover biospecimens.cancer.gov/bestpractices/to/) for and validate imaging biomarkers, and the molecular future trials and establish standard of procedures imaging community must continue to support research (SOP) to ensure sample quality, and implement and development of new molecular imaging techniques. these SOP’s in each protocol. The molecular imaging community must also come (III) Discontinue traditional blood handling procedures together, working with cooperative clinical trial groups which do not control the blood sitting temperature and the pharmaceutical industry, to support well-designed before processing and the interval between blood prospective trials validating molecular imaging biomarkers drawing and plasma preparation. Implement the © Translational lung cancer research. All rights reserved. tlcr.amegroups.com Transl Lung Cancer Res 2017;6(6):713-715 Translational Lung Cancer Research, Vol 6, No 6 October 2017 715 optimal procedure validated by the multicenter tissue in some settings, and that serial samples will be international study (2). increasingly useful in directing meaningful treatment (IV) Provide training sessions and/or detailed written decisions including aggressiveness of treatment and materials to research associates who are responsible